World's Best Scientists 2026 revealed!
Giuseppe Giaccone

Giuseppe Giaccone

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 143 1503 1390 871 795 868 83977

Giuseppe Giaccone publications per year

The chart shows the history of publications by Giuseppe Giaccone between 1970 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Giuseppe Giaccone published across 56 years, from 1970 to 2025, averaging 17.6 papers a year. Output peaked at 114 publications in 2023. 4 of the 985 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1970 to 2025. Vertical axis: number of publications, 0 to 114. Peak 114 publications in 2023. 1970: 1 publication 1971: 0 publications 1972: 0 publications 1973: 0 publications 1974: 0 publications 1975: 0 publications 1976: 0 publications 1977: 0 publications 1978: 0 publications 1979: 0 publications 1980: 0 publications 1981: 1 publication 1982: 0 publications 1983: 1 publication 1984: 4 publications 1985: 4 publications 1986: 5 publications 1987: 5 publications 1988: 10 publications 1989: 7 publications 1990: 3 publications 1991: 9 publications 1992: 10 publications 1993: 5 publications 1994: 12 publications 1995: 15 publications 1996: 18 publications 1997: 19 publications 1998: 18 publications 1999: 17 publications 2000: 25 publications 2001: 18 publications 2002: 31 publications 2003: 23 publications 2004: 33 publications 2005: 44 publications 2006: 31 publications 2007: 44 publications 2008: 30 publications 2009: 30 publications 2010: 46 publications 2011: 36 publications 2012: 34 publications 2013: 39 publications 2014: 32 publications 2015: 34 publications 2016: 34 publications 2017: 26 publications 2018: 32 publications 2019: 24 publications 2020: 22 publications 2021: 25 publications 2022: 10 publications 2023: 114 publications 2024: 1 publication 2025: 3 publications
1970 2025

985 publications in total across all disciplines

View publications per year as a table
Giuseppe Giaccone: publications per year, 1970 to 2025
Year Publications
1970 1
1971 0
1972 0
1973 0
1974 0
1975 0
1976 0
1977 0
1978 0
1979 0
1980 0
1981 1
1982 0
1983 1
1984 4
1985 4
1986 5
1987 5
1988 10
1989 7
1990 3
1991 9
1992 10
1993 5
1994 12
1995 15
1996 18
1997 19
1998 18
1999 17
2000 25
2001 18
2002 31
2003 23
2004 33
2005 44
2006 31
2007 44
2008 30
2009 30
2010 46
2011 36
2012 34
2013 39
2014 32
2015 34
2016 34
2017 26
2018 32
2019 24
2020 22
2021 25
2022 10
2023 114
2024 1
2025 3
Total 985
Download as CSV

Giuseppe Giaccone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giuseppe Giaccone sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 861–880 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 868 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155 868
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Giuseppe Giaccone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giuseppe Giaccone sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 142–143 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 143 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118 143
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Giuseppe Giaccone is affiliated with Cornell University in the United States and has a research focus primarily in medicine, with significant contributions to oncology, pulmonary and respiratory medicine, and neurology. Their work encompasses a broad range of topics including cancer immunotherapy and biomarkers, lung cancer treatments and mutations, as well as myasthenia gravis and thymoma.

Their research spans more than 130 publications in medicine, with 45 focused on oncology and 33 in pulmonary and respiratory medicine. Molecular biology and immunology are also notable subfields within their body of work.

Giuseppe Giaccone has published extensively in several key venues:

  • Journal of Thoracic Oncology
  • Clinical Lung Cancer
  • Journal of Clinical Oncology
  • Frontiers in Oncology
  • Annals of Oncology

Recent papers include:

  • Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC, 2020, New England Journal of Medicine
  • Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH, 2020, Cell Death and Differentiation
  • LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers, 2020, Cancer Letters
  • Thymic epithelial tumors: From biology to treatment, 2020, Cancer Treatment Reviews
  • Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung, 2020, Journal for ImmunoTherapy of Cancer

Frequent coauthors contributing jointly to the scientific output with Giuseppe Giaccone include:

  • Chul Kim
  • Roy S. Herbst
  • Filippo de Marinis
  • Jacek Jassem
  • Jordi Remón

The main topics addressed in their research are:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Myasthenia Gravis and Thymoma
  • Lung Cancer Research Studies
  • Immunotherapy and Immune Responses
  • Lung Cancer Diagnosis and Treatment
  • Pituitary Gland Disorders and Treatments

Best Publications

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

    Neal I. Lindeman;Philip T. Cagle;Mary Beth Beasley;Dhananjay Arun Chitale

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Targeting the dynamic HSP90 complex in cancer

    Jane Trepel;Mehdi Mollapour;Giuseppe Giaccone;Len Neckers

  • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

    Federico Cappuzzo;Tudor Ciuleanu;Lilia Stelmakh;Saulius Cicenas

  • Cell Death Independent of Caspases: A Review

    Linda E. Bröker;Frank A.E. Kruyt;Giuseppe Giaccone

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer

    Giorgio V. Scagliotti;Roldano Fossati;Valter Torri;Lucio Crinò

  • Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

    Jan P. van Meerbeeck;Rabab Gaafar;Christian Manegold;Rob J. Van Klaveren

  • Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer

    Jan P. van Meerbeeck;Gijs W. P. M. Kramer;Paul E. Y. Van Schil;Catherine Legrand

  • A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

    Giuseppe Giaccone;Cornelis J. A. Punt;Yoshitaka Ando;Rita Ruijter

  • Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Gregory A. Masters;Sarah Temin;Christopher G. Azzoli;Giuseppe Giaccone

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

    Vicki Leigh Keedy;Sarah Temin;Mark R. Somerfield;Mary Beth Beasley

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

Frequent Co-Authors

Egbert F. Smit
Egbert F. Smit VU University Medical Center
Godefridus J. Peters
Godefridus J. Peters Gdańsk Medical University
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Frank A.E. Kruyt
Frank A.E. Kruyt University Medical Center Groningen
Elisa Giovannetti
Elisa Giovannetti VU University Medical Center
Rik J. Scheper
Rik J. Scheper Amsterdam University Medical Centers
Jane B. Trepel
Jane B. Trepel National Institutes of Health
William D. Figg
William D. Figg National Institutes of Health
Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Paul S. Meltzer
Paul S. Meltzer National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking flexible education options or alternative career pathways, several online degrees and programs offer unique advantages. Nursing remains one of the most popular and versatile fields. Prospective nurses can benefit from an rn to bsn online no clinicals program, allowing registered nurses to earn their BSN degree without the need for additional clinical hours—an excellent option for working professionals.

Those aiming for advanced practice can explore short dnp programs and dnp online programs, designed for nurses with advanced degrees seeking a Doctor of Nursing Practice (DNP). These programs often feature accelerated curriculums or more accessible pathways, making it possible to advance your credentials without putting your current career on hold.

Additionally, those wanting a quicker entry into the healthcare workforce may consider fast track lpn options. These programs streamline the process of becoming a Licensed Practical Nurse, helping you launch your medical career in less time. With these diverse online opportunities, finding a program that suits your educational and professional goals has never been easier.

Best Scientists Citing Giuseppe Giaccone

Trending Scientists

Recently Published Articles